NOBOX

Summary

NOBOX (NOBOX oogenesis homeobox, HGNC:22448) is a protein-coding gene on chromosome 7q35, encoding Homeobox protein NOBOX (O60393). Transcription factor which may play a role in oogenesis.

This homeobox gene encodes a transcription factor that is thought to play a role in oogenesis. In mice, it is essential for folliculogenesis and regulation of oocyte-specific genes. Defects in this gene result in premature ovarian failure type 5.

Source: NCBI Gene 135935 — RefSeq curated summary.

At a glance

• Gene–disease (curated): premature ovarian failure 5 (Strong, GenCC)
• GWAS associations: 6
• Clinical variants (ClinVar): 218 total — 10 pathogenic, 6 likely-pathogenic
• Phenotypes (HPO): 7

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22448
Approved symbol	NOBOX
Name	NOBOX oogenesis homeobox
Location	7q35
Locus type	gene with protein product
Status	Approved
Aliases	OG2, Og2x
Ensembl gene	ENSG00000106410
Ensembl biotype	protein_coding
OMIM	610934
Entrez	135935

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000467773, ENST00000643164, ENST00000645489

RefSeq mRNA: 1 — MANE Select: None NM_001080413

CCDS: CCDS47736

Canonical transcript exons

ENST00000467773 — 10 exons

Exon	Start	End
ENSE00000729273	144399397	144399482
ENSE00000729276	144399757	144399863
ENSE00000729280	144401046	144401597
ENSE00001505566	144400110	144400312
ENSE00001550402	144401869	144401950
ENSE00001554893	144404556	144404680
ENSE00001557808	144410143	144410227
ENSE00001681449	144398282	144398586
ENSE00001702350	144398950	144399178
ENSE00003642859	144397240	144397541

Expression profiles

Bgee: expression breadth tissue_specific, 8 present calls, max score 69.06.

Top tissues by expression

128 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	69.06	gold quality
colonic epithelium	UBERON:0000397	37.20	gold quality
granulocyte	CL:0000094	36.79	gold quality
right testis	UBERON:0004534	36.50	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
bone marrow cell	CL:0002092	36.16	gold quality
apex of heart	UBERON:0002098	35.54	gold quality
ganglionic eminence	UBERON:0004023	35.49	gold quality
testis	UBERON:0000473	35.14	gold quality
left testis	UBERON:0004533	33.85	silver quality
skeletal muscle tissue	UBERON:0001134	33.38	gold quality
bone marrow	UBERON:0002371	32.88	gold quality
muscle tissue	UBERON:0002385	32.17	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
leukocyte	CL:0000738	30.30	gold quality
prefrontal cortex	UBERON:0000451	30.22	gold quality
monocyte	CL:0000576	29.95	gold quality
stromal cell of endometrium	CL:0002255	29.87	gold quality
vermiform appendix	UBERON:0001154	29.34	gold quality
liver	UBERON:0002107	28.57	gold quality
duodenum	UBERON:0002114	28.14	gold quality
lymph node	UBERON:0000029	27.57	gold quality
smooth muscle tissue	UBERON:0001135	27.46	gold quality
tonsil	UBERON:0002372	27.05	gold quality
cortex of kidney	UBERON:0001225	27.02	gold quality
islet of Langerhans	UBERON:0000006	26.97	gold quality
superior frontal gyrus	UBERON:0002661	26.82	gold quality
blood	UBERON:0000178	26.78	gold quality
kidney	UBERON:0002113	26.23	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.16

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

3 targets.

Target	Regulation
BGLAP
GDF9
POU5F1	Unknown

Upstream regulators (CollecTRI, top): CEBPD, CEBPG, RUNX2

Literature-anchored findings (GeneRIF, showing 14)

• Mutations of the homeobox region of the NOBOX gene are uncommon in Japanese patients with premature ovarian failure. (PMID:15950662)
• NOBOX expression within adult human tissues is limited to the testis, pancreas and oocyte specific in ovary. (PMID:16597639)
• These findings demonstrate that NOBOX mutations can cause premature ovarian failure. (PMID:17701902)
• Mutations in the homeobox domain of NOBOX are not common explanations for POF in Chinese women. (PMID:18930203)
• The very high 6.2% prevalence of these new mutations in POI patients suggest considering NOBOX as the first autosomal candidate gene involved in this syndrome. (PMID:21837770)
• both NOBOX and FOXL2 are expressed in human follicle granulosa cells and their interaction plays an inhibitory role in the transcriptional response of these promoters. (PMID:24620032)
• High prevalence of the association between the NOBOX rare variants and Primary ovarian insufficiency. (PMID:25514101)
• Screening of NOBOX gene indicted three missense mutations (p.Arg117Trp; p.Gly91Trp and p.Pro619Leu) in eight patients with primary ovarian insufficiency. (PMID:26848058)
• we report the identification of two novel and two recurrent heterozygous NOBOX variants in 7 out of 107 patients, with a prevalence of 6.5% (upper 95% confidence limit of 11.17%). Several variants conserve the ability to interact with FOXL2 in intracellular aggregates (PMID:27798098)
• One novel homozygous truncating variant, chr7:144098161delC, in the NOBOX gene was found in a primary ovarian insufficiency patient. The truncating variant showed a severe defect in transcriptional activation of GDF9 a well-known target of NOBOX. Many oocyte-related genes were expressed at lower level in truncating variant cells than in control cells. We found the truncated NOBOX lost its ability to induced G2/M arrest. (PMID:27836978)
• RSPO2 is a novel target gene of the NOBOX key transcription factor, confirming its important role during the follicular growth in ovary. However, RSPO2 mutations are rare or uncommon in women with primary ovarian insufficiency. (PMID:28743298)
• We report the first familial case of a novel homozygous NOBOX variant with an autosomal recessive mode of inheritance, thus allowing for a genetic diagnosis of primary ovarian failure (PMID:29067606)
• Compound heterozygous null mutations of NOBOX in sisters with delayed puberty and primary amenorrhea. (PMID:34480423)
• NOBOX gene variants in premature ovarian insufficiency: ethnicity-dependent insights. (PMID:37921973)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Nobox	ENSMUSG00000029736
rattus_norvegicus	Nobox	ENSRNOG00000025720

Paralogs (50): ARX (ENSG00000004848), PAX6 (ENSG00000007372), PAX7 (ENSG00000009709), ALX4 (ENSG00000052850), GSC2 (ENSG00000063515), PITX1 (ENSG00000069011), PAX2 (ENSG00000075891), RHOXF1 (ENSG00000101883), CRX (ENSG00000105392), EVX1 (ENSG00000106038), PAX4 (ENSG00000106331), PITX3 (ENSG00000107859), PHOX2B (ENSG00000109132), OTX1 (ENSG00000115507), PRRX1 (ENSG00000116132), VSX2 (ENSG00000119614), ESX1 (ENSG00000123576), PAX8 (ENSG00000125618), PAX1 (ENSG00000125813), RHOXF2 (ENSG00000131721), GSC (ENSG00000133937), RAX (ENSG00000134438), PAX3 (ENSG00000135903), ALX3 (ENSG00000156150), HESX1 (ENSG00000163666), PITX2 (ENSG00000164093), UNCX (ENSG00000164853), PHOX2A (ENSG00000165462), OTX2 (ENSG00000165588), DRGX (ENSG00000165606), PRRX2 (ENSG00000167157), SHOX2 (ENSG00000168779), OTP (ENSG00000171540), RAX2 (ENSG00000173976), EVX2 (ENSG00000174279), PROP1 (ENSG00000175325), ISX (ENSG00000175329), ALX1 (ENSG00000180318), MIXL1 (ENSG00000185155), SHOX (ENSG00000185960)

Protein

Protein identifiers

Homeobox protein NOBOX — O60393 (reviewed: O60393)

All UniProt accessions (3): O60393, A0A2R8Y683, A0A2R8Y8C8

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor which may play a role in oogenesis. Binds preferentially to the DNA sequences 5’-TAATTG-3’, 5’-TAGTTG-3’ and 5’-TAATTA-3'.

Subcellular location. Nucleus.

Tissue specificity. Expressed in ovaries, testes and pancreas. Expressed within all stages of the adult female germline, from primordial follicles through to MII oocytes.

Disease relevance. Premature ovarian failure 5 (POF5) [MIM:611548] An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (2)

UniProt ID	Names	Canonical?
O60393-1	1	yes
O60393-2	2

RefSeq proteins (1): NP_001073882 (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001356	HD	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR042988	NOBOX	Family

Pfam: PF00046

UniProt features (27 total): sequence variant 15, compositionally biased region 5, region of interest 4, chain 1, DNA-binding region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60393-F1	48.12	0.03

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9820841	M-decay: degradation of maternal mRNAs by maternally stored factors

MSigDB gene sets: 53 (showing top): GOBP_OOGENESIS, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, GOBP_FEMALE_GAMETE_GENERATION, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, chr7q35, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, MIKKELSEN_ES_ICP_WITH_H3K4ME3, ESC_J1_UP_LATE.V1_DN, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, GSE13547_WT_VS_ZFX_KO_BCELL_ANTI_IGM_STIM_2H_DN, GSE10239_MEMORY_VS_KLRG1HIGH_EFF_CD8_TCELL_UP, GSE13306_RA_VS_UNTREATED_TREG_DN, GSE13485_CTRL_VS_DAY3_YF17D_VACCINE_PBMC_UP, GSE13485_DAY1_VS_DAY3_YF17D_VACCINE_PBMC_UP, GSE14308_TH2_VS_NATURAL_TREG_UP

GO Biological Process (3): regulation of transcription by RNA polymerase II (GO:0006357), oogenesis (GO:0048477), cell differentiation (GO:0030154)

GO Molecular Function (5): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), sequence-specific DNA binding (GO:0043565), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700)

GO Cellular Component (2): chromatin (GO:0000785), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Maternal to zygotic transition (MZT)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
transcription by RNA polymerase II	1
germ cell development	1
female gamete generation	1
cellular developmental process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
DNA binding	1
nucleic acid binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
chromosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

848 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NOBOX	FIGLA	Q6QHK4	978
NOBOX	SOHLH1	Q5JUK2	942
NOBOX	BMP15	O95972	935
NOBOX	GDF9	O60383	930
NOBOX	LHX8	Q68G74	928
NOBOX	FOXL2	P58012	895
NOBOX	YBX2	Q9Y2T7	880
NOBOX	POF1B	Q8WVV4	869
NOBOX	SOHLH2	Q9NX45	748
NOBOX	ZP3	P21754	743
NOBOX	FMR1	Q06787	729
NOBOX	POU5F1	P31359	694
NOBOX	DIAPH2	O60879	693
NOBOX	NR5A1	Q13285	680
NOBOX	ZP1	P60852	659

IntAct

2 interactions, top by confidence:

A	B	Type	Score
NOBOX	CDK2	psi-mi:“MI:0914”(association)	0.350

BioGRID (5): CCNJ (Affinity Capture-MS), DHX32 (Affinity Capture-MS), C5orf22 (Affinity Capture-MS), CDK2 (Affinity Capture-MS), CDK5RAP2 (Affinity Capture-MS)

ESM2 similar proteins: A0A5F9ZHS7, A1YGK1, A2T7E6, A8MZG2, O08574, O43593, O60393, O75593, O88621, O95231, P0C1T1, P0CG20, P20428, P97609, Q04667, Q17QR5, Q2KIS6, Q2M1V0, Q2T9Q7, Q32LE6, Q497V6, Q5JUK2, Q5M844, Q5RJB0, Q5TGS1, Q61645, Q61657, Q6ZMY3, Q6ZN32, Q6ZNG2, Q7RTU1, Q8BZW2, Q8CGW9, Q8IWN7, Q8IXT2, Q8IZ20, Q8N1L9, Q8N7G0, Q8N944, Q8N9Y4

Diamond homologs: A1YG25, A2T711, A6NJT0, A6NNA5, A6YP92, G5EC89, O08934, O09113, O14813, O15266, O35085, O35137, O35160, O35602, O35690, O35750, O42115, O42250, O42357, O42358, O42477, O60393, O60902, O70137, O75364, O76971, O93385, O95076, O97039, P0DMV5, P23759, P29506, P41935, P47239, P54821, P56672, P58304, P63013, P63014, P70314

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

218 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	10
Likely pathogenic	6
Uncertain significance	136
Likely benign	24
Benign	32

Top pathogenic / likely-pathogenic (16)

Variant ID	HGVS	Classification
1255994	NM_001436401.1(NOBOX):c.1690dup (p.Ala564fs)	Pathogenic
1256025	NM_001436401.1(NOBOX):c.780del (p.Gly261fs)	Pathogenic
1256031	NM_001436401.1(NOBOX):c.1323_1326del (p.Phe442fs)	Pathogenic
167873	NM_001436401.1(NOBOX):c.652C>T (p.Arg218Ter)	Pathogenic
167876	NM_001436401.1(NOBOX):c.696+74G>C	Pathogenic
167877	NM_001436401.1(NOBOX):c.697G>T (p.Val233Leu)	Pathogenic
2426756	NC_000007.13:g.(?144094333)(144532695_?)del	Pathogenic
3376873	NM_001436401.1(NOBOX):c.958del (p.Val320fs)	Pathogenic
957395	NM_001436401.1(NOBOX):c.971del (p.Pro324fs)	Pathogenic
970942	NM_001436401.1(NOBOX):c.696+23_696+24dup	Pathogenic
1256013	NM_001436401.1(NOBOX):c.947G>T (p.Gly316Val)	Likely pathogenic
1256030	NM_001436401.1(NOBOX):c.848C>T (p.Pro283Leu)	Likely pathogenic
2630292	NM_001436401.1(NOBOX):c.1138del (p.Cys380fs)	Likely pathogenic
4081552	NM_001080413.3(NOBOX):c.120T>A (p.Cys40Ter)	Likely pathogenic
812129	NM_001436401.1(NOBOX):c.727C>T (p.Arg243Ter)	Likely pathogenic
929756	NM_001436401.1(NOBOX):c.1089G>C (p.Lys363Asn)	Likely pathogenic

SpliceAI

1318 predictions. Top by Δscore:

Variant	Effect	Δscore
7:144398585:TG:T	acceptor_gain	1.0000
7:144399048:A:T	acceptor_gain	1.0000
7:144399392:CTCA:C	donor_loss	1.0000
7:144399393:TCACC:T	donor_loss	1.0000
7:144399394:CA:C	donor_loss	1.0000
7:144399395:A:AG	donor_loss	1.0000
7:144399483:C:CC	acceptor_gain	1.0000
7:144399490:C:CT	acceptor_gain	1.0000
7:144399753:TGAC:T	donor_loss	1.0000
7:144399754:GACC:G	donor_loss	1.0000
7:144399859:CACAC:C	acceptor_gain	1.0000
7:144399861:CAC:C	acceptor_gain	1.0000
7:144399864:CT:C	acceptor_loss	1.0000
7:144399865:T:C	acceptor_loss	1.0000
7:144400203:TAC:T	donor_loss	1.0000
7:144400205:CCA:C	donor_loss	1.0000
7:144400257:A:AC	donor_gain	1.0000
7:144400308:CTGAT:C	acceptor_gain	1.0000
7:144400309:TGAT:T	acceptor_gain	1.0000
7:144400310:GAT:G	acceptor_gain	1.0000
7:144400311:AT:A	acceptor_gain	1.0000
7:144400313:C:CC	acceptor_gain	1.0000
7:144398366:C:CT	acceptor_gain	0.9900
7:144398511:T:TA	donor_gain	0.9900
7:144398582:TGATG:T	acceptor_gain	0.9900
7:144398587:C:CC	acceptor_gain	0.9900
7:144398944:CCTTA:C	donor_loss	0.9900
7:144398945:CTTAC:C	donor_loss	0.9900
7:144398946:TTA:T	donor_loss	0.9900
7:144398948:A:C	donor_loss	0.9900

AlphaMissense

4442 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:144400284:G:C	F291L	0.998
7:144400284:G:T	F291L	0.998
7:144400286:A:G	F291L	0.998
7:144399855:G:C	F352L	0.997
7:144399855:G:T	F352L	0.997
7:144399857:A:G	F352L	0.997
7:144400240:G:T	A306D	0.997
7:144399832:C:G	R360P	0.996
7:144400285:A:G	F291S	0.996
7:144399856:A:G	F352S	0.995
7:144400297:A:G	L287P	0.995
7:144401055:A:C	Y279D	0.994
7:144399848:G:T	R355S	0.993
7:144400210:A:G	I316T	0.993
7:144400253:G:T	R302S	0.993
7:144400285:A:C	F291C	0.992
7:144399837:C:A	K358N	0.991
7:144399837:C:G	K358N	0.991
7:144399847:C:G	R355P	0.991
7:144400210:A:C	I316S	0.991
7:144400241:C:G	A306P	0.990
7:144399834:C:A	W359C	0.989
7:144399834:C:G	W359C	0.989
7:144399836:A:G	W359R	0.989
7:144399836:A:T	W359R	0.989
7:144400252:C:G	R302P	0.989
7:144399856:A:C	F352C	0.988
7:144400286:A:C	F291V	0.988
7:144400306:A:G	L284P	0.987
7:144399849:A:C	N354K	0.986

dbSNP variants (sampled 300 via entrez): RS1000047551 (7:144402580 C>A,G,T), RS1000063719 (7:144404804 A>C,G,T), RS1000109299 (7:144411509 G>A), RS1000118071 (7:144408383 G>A), RS1000172259 (7:144407993 T>C), RS1000398729 (7:144402878 TC>T), RS1000451863 (7:144406897 T>C), RS1000503515 (7:144406608 T>A), RS1000883825 (7:144412148 A>G), RS1001022982 (7:144404013 T>G), RS1001229494 (7:144408143 C>A), RS1001293169 (7:144397456 T>G), RS1001558639 (7:144403022 G>A), RS1001815748 (7:144408819 G>A,T), RS1001818488 (7:144408796 G>A)

Disease associations

OMIM: gene MIM:610934 | disease phenotypes: MIM:611548, MIM:614458, MIM:311360, MIM:114480

GenCC curated gene-disease

Disease	Classification	Inheritance
premature ovarian failure 5	Strong	Autosomal dominant

Mondo (5): premature ovarian failure 5 (MONDO:0012689), childhood encephalopathy due to thiamine pyrophosphokinase deficiency (MONDO:0013761), premature ovarian failure 1 (MONDO:0010706), hereditary breast carcinoma (MONDO:0016419), primary ovarian failure (MONDO:0005387)

Orphanet (5): Rare genetic premature ovarian failure (Orphanet:485382), Childhood encephalopathy due to thiamine pyrophosphokinase deficiency (Orphanet:293955), Fragile X-associated primary ovarian insufficiency (Orphanet:642691), Hereditary breast cancer (Orphanet:227535), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

7 total (7 of 7 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000786	Primary amenorrhea
HP:0000869	Secondary amenorrhea
HP:0008209	Premature ovarian insufficiency
HP:0008724	Hypoplasia of the ovary
HP:0010464	Streak ovary
HP:0033085	Reduced antral follicle count

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001937_6	Breast cancer	7.000000e-11
GCST004988_267	Breast cancer	1.000000e-11
GCST005169_4	Diastolic blood pressure	4.000000e-06
GCST009391_862	Metabolite levels	9.000000e-06
GCST010136_23	Fruit consumption	5.000000e-08
GCST010136_24	Fruit consumption	1.000000e-48

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0010533	sorbitol measurement
EFO:0008111	diet measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750
C562840	Breast Cancer, Familial (supp.)
C566921	Premature Ovarian Failure 5 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

4 total (human), top 4 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Arsenic	affects methylation	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
Particulate Matter	increases methylation	1

Clinical trials (associated diseases)

92 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT05687474	Not specified	COMPLETED	Baby Detect : Genomic Newborn Screening
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT00471731	Not specified	COMPLETED	Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure
NCT01023178	Not specified	COMPLETED	Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure
NCT01177891	Not specified	COMPLETED	Genetic Analysis of Familial Cases of Premature Ovarian Failure
NCT02780791	Not specified	TERMINATED	Maturation of Follicles After Transplantation of Ovarian Tissue Into the Pelvic Wall and the Ovary
NCT05443282	Not specified	COMPLETED	Ovarian Reserve and Matrix Metalloproteinases
NCT07117682	Not specified	NOT_YET_RECRUITING	Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve
NCT00040222	Not specified	COMPLETED	Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
NCT02557776	Not specified	COMPLETED	Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer
NCT03495544	Not specified	UNKNOWN	Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer
NCT03959267	Not specified	COMPLETED	Testing a Culturally Adapted Telephone Genetic Counseling Intervention
NCT04058418	Not specified	COMPLETED	Specialist Recommendation on FBC (Familial Breast Cancer) Chemoprevention Prescribing
NCT04125914	Not specified	ACTIVE_NOT_RECRUITING	Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families
NCT04169542	Not specified	RECRUITING	Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
NCT04197856	Not specified	ACTIVE_NOT_RECRUITING	Direct Information to At-risk Relatives
NCT07292246	Not specified	RECRUITING	A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)
NCT07307664	Not specified	RECRUITING	Increasing Germline Genetic Testing for Patients With Cancer
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure